As 1 type of immune checkpoint inhibitors (ICIs), programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors showed some therapeutic benefit for ultra-high-risk GTN patients with multiagent chemotherapy resistance.[13–15] Several studies have demonstrated a high level of PD-L1 expression in GTN,[16–18] suggesting that PD-1/PD-L1 inhibitors may be an effective therapeutic strategy. The gene discussed is PDCD1; the disease is gestational trophoblastic neoplasm.